Impact of A. Lumbricoides on Pulmonary Aspergillosis Development

Role of A. Lumbricoides in the Development of Pulmonary Aspergillosis in Chronic Obstructive Pulmonary Disease Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05783544

Enrollment

200

Registered

2023-03-24

Start date

2015-05-01

Completion date

2025-12-31

Last updated

2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation Acute, Ascaris Lumbricoides Infection, Chronic Pulmonary Aspergillosis

Keywords

COPD, aspergillosis, ascariasis, cytokines, helminths

Brief summary

The prevalence of ascariasis in COPD patients with and without concomitant pulmonary aspergillosis and in controls will be determined. To assess the influence of ascaridosis on the development of pulmonary aspergillosis in COPD patients cytokine status of patients will be studied.

Interventions

DIAGNOSTIC_TESTInterleukin-1B

Level of serum interleukin-1B will be detected

DIAGNOSTIC_TESTInterleukin-4

Level of serum interleukin-4 will be detected

DIAGNOSTIC_TESTInterleukin-6

Level of serum interleukin-4 will be detected

DIAGNOSTIC_TESTtumor necrosis factor - a

Level of serum tumor necrosis factor - a will be detected

DIAGNOSTIC_TESTinterferon- gamma

Level of serum interferon- gamma will be detected

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 100 Years

Healthy volunteers

Yes

Inclusion criteria

* COPD patients * COPD patients with aspergillosis * COPD patients with ascariasis * COPD patients with mix-infection * Healthy individuals (controls)

Exclusion criteria

* COPD patients with other autoimmune diseases * COPD patients with oncological diseases * COPD patients with other co-infections

Design outcomes

Primary

Measure	Time frame	Description
Serum interleukin-6 levels in COPD patients and controls	up to 12 months	Serum interleukin-6 (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Serum interleukin-1B levels in COPD patients and controls	up to 12 months	Serum interleukin-1B (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Serum interleukin-4 levels in COPD patients and controls	up to 12 months	Serum interleukin-4 (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Correlation between cytokine status with chronic pulmonary aspergilosis insidence rate in COPD patients with and without ascariasis	up to 12 months	The correlation between serum interleukin-1B, interleukin-4, interleukin-6, tumor necrosis factor-a and interferon-y levels with chronic pulmonary aspergilosis insidence rate in COPD patients with and without ascariasis will be assessed.
Serum tumor necrosis factor-a levels in COPD patients and controls	up to 12 months	Serum tumor necrosis factor-a (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Serum interferon-gamma levels in COPD patients and controls	up to 12 months	Serum interferon-gamma (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.

Secondary

Measure	Time frame	Description
Rate of ascariasis infestation among COPD patients and controls	up to 12 months	The frequency of ascariasis infestation among COPD patients with and without pulmonary aspergillosis, as well as healthy individuals, will be assessed.

Countries

Uzbekistan

Contacts

Primary ContactAbdurakhim Dr Toychiev, PhD

abdurahim1988@gmail.com+998901358977

Backup ContactSvetlana Dr Osipova, PhD

svetosip7@mail.ru+998712774008

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026